Top

Published in:

Open Access 01-12-2017 | Research

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Authors: Yunqiang Nie, Wei Gao, Na Li, Wenjun Chen, Hui Wang, Cuiyun Li, Haiyan Zhang, Ping Han, Yingmei Zhang, Xin Lv, Xinyi Xu, Hongyan Liu

Published in: World Journal of Surgical Oncology | Issue 1/2017

Abstract

Background

Resectable lung adenocarcinoma is dominated by peripheral distribution, and surgical resection is the main treatment protocol. However, high recurrence rate remains after surgery. Lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation has strong invasion ability, but the effects of this mutation on local invasion in early lung adenocarcinoma have been rarely studied. This study aimed to assess the effects of EGFR mutation on local invasion in resectable lung adenocarcinoma.

Methods

A retrospective analysis of 103 patients clinically diagnosed with peripheral lung adenocarcinoma was included. They underwent preoperative bronchoscopy, which indicated grades 2 or 3 bronchial involvement (lumen of the lobe or segment). The associations of EGFR mutation with pleural invasion, endobronchial metastasis, and lymph node metastasis were analyzed according to pathologies of pleural invasion and lymph node metastasis, as well as EGFR gene mutation detected by postoperative pathological specimens. Statistical analyses were performed by unpaired Chi-square test using the SPSS16.0 software.

Results

In patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 62.5, 39.1, and 34.4%, respectively, indicating statistically significant differences (p = 0.003). Meanwhile, the pleural invasion rate in patients with wild-type EGFR was 43.6%, significantly reduced compared with patients with mutated EGFR (62.5%; p = 0.018). In addition, the endobronchial metastasis rate in patients with wild-type EGFR was 17.9%, significantly lower than in patients with EGFR mutation (39.1%; p = 0.005). However, lymph node metastasis rates were similar between EGFR mutated and wild-type patients (34.4 vs 25.6%, respectively, p > 0.05).

Conclusions

Early resectable lung adenocarcinoma patients with EGFR mutation showed a higher rate of local invasion compared with those harboring wild-type EGFR. This finding provides a basis for improved therapy.

Trial registration

This study was supported by Project of Medical and Health Science Technology in Shandong Province (2015WS0376)

Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.CrossRefPubMed

Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012;23:2914–9.CrossRefPubMed

Tomaszek SC, Kim Y, Cassivi SD, et al. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg. 2011;40:1151–6.PubMed

Rabahi MF, Ferreira AA, Reciputti BP, et al. Fiberoptic bronchoscopy findings in patients diagnosed with lung cancer. J Bras Pneumol. 2012;38:445–51.CrossRefPubMed

Griffin JP, Zaman MK, Niell HB, et al. Diagnosis of lung cancer: a bronchoscopist's perspective. J Bronchology Interv Pulmonol. 2012;19:12–8.CrossRefPubMed

Sienel W, Stremmel C, Kirschbaum A, et al. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for segmentectomy. Eur J Cardiothorac Surg. 2007;31:522–7. discussion 7-8.CrossRefPubMed

Berthet JP, Paradela M, Jimenez MJ, et al. Extended sleeve lobectomy: one more step toward avoiding pneumonectomy in centrally located lung cancer. Ann Thorac Surg. 2013;96:1988–97.CrossRefPubMed

Hofmann HS, Taege C, Lautenschlager C, et al. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;21:606–10.CrossRefPubMed

Riquet M, Achour K, Foucault C, et al. Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. Ann Thorac Surg. 2010;89:870–5.CrossRefPubMed

10.

Horinouchi H, Nomori H, Nakayama T, et al. How many pathological T1N0M0 non-small cell lung cancers can be completely resected in one segment? Special reference to high-resolution computed tomography findings. Surg Today. 2011;41:1062–6.CrossRefPubMed

11.

Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer. 2011;71:156–65.CrossRefPubMed

12.

Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129:87–93.CrossRefPubMed

13.

El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14:2400–5.CrossRefPubMed

14.

Canizares MA, Matilla JM, Cueto A, et al. Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax. 2014;69:648–53.CrossRefPubMed

15.

Koike T, Koike T, Yoshiya K, et al. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:372–8.CrossRefPubMed

16.

Collaud S, Bongiovanni M, Pache JC, et al. Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:622–6.CrossRefPubMed

17.

Riquet M, Lang-Lazdunski L, Le PB, et al. Characteristics and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg. 2002;73:253–8.CrossRefPubMed

18.

Smits AJ, Kummer JA, Hinrichs JW, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr). 2012;35:189–96.CrossRef

19.

Iyoda A, Hiroshima K, Moriya Y, et al. Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today. 2010;40:725–8.CrossRefPubMed

20.

Yano T, Morodomi Y, Ito K, et al. Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size. J Thorac Oncol. 2010;5:45–8.CrossRefPubMed

21.

Deng LL, Deng HB, Lu CL, et al. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140:2097–105.CrossRefPubMed

22.

Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol. 2011;41:548–54.CrossRefPubMed

23.

Masasyesva BG, Tong BC, Brock MV, et al. Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. Int J Cancer. 2005;113:1022–5.CrossRefPubMed

24.

Ahn HK, Choi YL, Han JH, et al. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer. 2013;79:300–6.CrossRefPubMed

25.

Chen C, Bao F, Zheng H, et al. Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. Ann Thorac Surg. 2012;93:389–96.CrossRefPubMed

26.

Zaric B, Stojsic V, Kovacevic T, et al. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma. J Thorac Oncol. 2014;9:1406–10.CrossRefPubMed

27.

Saisho S, Yasuda K, Maeda A, et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg. 2013;16:166–72.CrossRefPubMed

28.

Sonobe M, Kobayashi M, Ishikawa M, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol. 2012;19 Suppl 3:S347–54.CrossRefPubMed

Title: Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma
Authors: Yunqiang Nie
Wei Gao
Na Li
Wenjun Chen
Hui Wang
Cuiyun Li
Haiyan Zhang
Ping Han
Yingmei Zhang
Xin Lv
Xinyi Xu
Hongyan Liu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-017-1103-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma

Symptoms and signs associated with benign and malignant proximal fibular tumors: a clinicopathological analysis of 52 cases

Sclerosing mesenteritis mimicking metachronous peritoneal metastases from descending colon adenocarcinoma

Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

Preoperative detection of pleural adhesions by respiratory dynamic computed tomography

Medical treatment of mammary desmoid-type fibromatosis: which benefit?